|
|
 | | | |
- close
- close
- close
- close
StreetInsider.com
Mar 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Marina+Biotech+%28MRNA%29%2C+ProNA+Enter+DNAi-Based+Therapeutic+Licensing+Agreement/7267334.html for the full story.
Marketwire
Jan 25
Comment
BOTHELL, WA -- (Marketwire) -- 01/25/12 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability
StreetInsider.com
Jan 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Marina+Biotech+%28MRNA%29+Files+6M+Shelf+for+Shareholders/7079924.html for the full story.
StreetInsider.com
Nov 30
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Marina+Biotech+%28MRNA%29+Granted+Request+for+Continued+Nasdaq+Listing/6983229.html for the full story.
Marketwire
Nov 29
Comment
BOTHELL, WA -- (Marketwire) -- 11/29/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, today announced that the Marina/Debiopharm Research and Development (R&D) Team has selected and
Marketwire
Nov 18
Comment
NEW YORK, NY -- (Marketwire) -- 11/18/11 -- Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper Inc. healthcare and biotechnology stock funds
Marketwire
Nov 17
Comment
BOTHELL, WA -- (Marketwire) -- 11/17/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, reported that the State Intellectual Property Office of the People's Republic of China (PRC) has
Marketwire
Nov 10
Comment
BOTHELL, WA -- (Marketwire) -- 11/10/11 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, today reported financial results for the three and nine months ended September 30, 2011, and
Marketwire
Nov 3
Comment
NEW YORK, NY -- (Marketwire) -- 11/03/11 -- The long journey through various stages of approval can make or break biotech companies that have spent countless hours and dollars on research and development. While many companies fail, the biotech
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
MRNA has shown some positive signs, yet it seems to still be avoided by investors. Until investors see that it is going to be profitable. However, MRNA's lack of compliance with the Nasdaq requirements will also have a negative affect on its stock's chances of success.
| |||||||
